GO:2000504 positive regulation of blood vessel remodeling: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000504 (positive regulation of blood vessel remodeling) describes any process that activates or increases the frequency, rate or extent of blood vessel remodeling, a dynamic structural adaptation of the vessel wall.
• Vascular remodeling is driven by endothelial, smooth muscle, pericyte and immune cell programs that converge on proliferation, migration, matrix turnover and metabolic reprogramming.
• Metabolic intermediates such as lactate and glycolytic enzymes (HK2, LDHA) act as direct positive regulators of vascular remodeling in tumors and pulmonary hypertension.
• Epigenetic regulators including METTL14 and histone lactylation control the transcriptional permissiveness of remodeling genes in vascular cells.
• Dysregulated positive regulation of blood vessel remodeling underlies aortic aneurysm, pulmonary arterial hypertension, atherosclerosis and tumor vascular abnormalities.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of candidate remodeling regulators in endothelial and smooth muscle cells.
Description
GO:2000504, positive regulation of blood vessel remodeling, is a Gene Ontology biological process term that captures any signal or molecular event that activates or increases the frequency, rate or extent of blood vessel remodeling. Blood vessel remodeling is the structural and functional reorganization of the vessel wall in response to hemodynamic, metabolic or inflammatory cues, and it is essential for development, wound healing and tumor angiogenesis. Because remodeling is a rate process, the positive regulation branch of the ontology is used to annotate genes and pathways that accelerate or amplify it rather than those that simply execute it. Researchers studying vascular biology, cardio-oncology and pulmonary disease rely on GO:2000504 to group mechanistically diverse regulators, from metabolic enzymes to epigenetic writers, under a single functional umbrella. The term is therefore a practical entry point for hypothesis generation: any gene annotated to GO:2000504 is a candidate causal driver of vessel-wall change and a potential target for CRISPR perturbation.
positive regulation of blood vessel remodeling At A Glance
| GO ID | GO:2000504 |
|---|---|
| GO term | positive regulation of blood vessel remodeling |
| Ontology | biological_process |
| Synonym | positive regulation of blood vessel remodelling |
| Definition | Any process that activates or increases the frequency, rate or extent of blood vessel remodeling. |
| Major function | Upregulation of structural and functional reorganization of the vessel wall, including endothelial, smooth muscle and pericyte contributions. |
| Biological context | Development, tumor angiogenesis, pulmonary hypertension, aortic aneurysm and post-infarction cardiac remodeling. |
| Representative regulators | METTL14, ARG1, HK2, LDHA, CARD9, GATA6, CLU. |
| Research relevance | Provides a functional grouping for causal CRISPR screens and target validation in vascular disease models. |
What Is GO:2000504?
In plain terms, GO:2000504 describes the set of biological activities that switch blood vessel remodeling on or turn it up. The official QuickGO definition states that it is any process that activates or increases the frequency, rate or extent of blood vessel remodeling. It is a biological_process term, and its synonym is positive regulation of blood vessel remodelling. Functionally, it sits above the execution machinery of remodeling and below the upstream stimuli, so it is used to annotate regulators such as metabolic enzymes, epigenetic modifiers and signaling adaptors that quantitatively enhance vessel-wall restructuring.
Why Is positive regulation of blood vessel remodeling Important in Cell Biology?
Positive regulation of blood vessel remodeling is important because the same process that supports physiological angiogenesis and tissue repair becomes pathogenic when chronically activated, driving aneurysm, pulmonary hypertension and tumor vascular abnormalities. Annotating genes to GO:2000504 helps researchers separate accelerators of remodeling from bystanders, which is critical when selecting therapeutic targets or designing CRISPR validation experiments.
• Defines the accelerator arm of vascular remodeling, distinguishing causal regulators from downstream effectors.
• Links metabolic reprogramming, including glycolysis and lactate production, to vessel-wall structural change.
• Connects epigenetic regulation such as METTL14-dependent methylation and histone lactylation to remodeling gene expression.
• Provides a framework for studying pulmonary vascular remodeling in pulmonary arterial hypertension.
• Supports mechanistic dissection of aortic aneurysm and dissection through smooth muscle metabolic remodeling.
• Explains tumor blood vessel abnormalities driven by pericyte contractility and glycolysis.
• Enables functional annotation of immune regulators such as CARD9 in post-infarction cardiac injury.
• Guides CRISPR knockout and knock-in design for causal testing of candidate remodeling genes.
• Helps prioritize biomarkers such as clusterin in pressure-overload cardiac remodeling.
• Underpins rational target selection for anti-remodeling therapies in cardiovascular and oncologic disease.
What Happens During positive regulation of blood vessel remodeling?
Initiation by metabolic and hypoxic cues
In simple terms: The process often starts when cells in the vessel wall sense low oxygen or altered metabolism and switch on remodeling programs.
Ischemia and hypoxia trigger mitochondrial cristae remodeling and inflammatory cell death programs in vascular cells, and arginase 1 has been shown to drive this mitochondrial remodeling and PANoptosis during ischemia/hypoxia-induced vascular dysfunction. In pulmonary hypertension, lactate dehydrogenase A mediated lactate generation promotes pulmonary vascular remodeling, indicating that glycolytic flux is an upstream positive regulator of the process. These metabolic cues convert environmental stress into biochemical signals that increase the rate of vessel-wall restructuring.
Epigenetic permissiveness and transcriptional activation
In simple terms: Chemical marks on DNA-associated proteins and RNA-modifying enzymes open the chromatin so remodeling genes can be expressed.
Deletion of METTL14, a key methylation regulator, attenuates vascular ageing, demonstrating that RNA methylation status positively regulates age-related vascular remodeling programs. Histone lactylation-mediated metabolic remodeling in vascular smooth muscle cells aggravates aortic aneurysm and dissection by promoting lactate accumulation, linking chromatin modification directly to remodeling gene expression. Together these findings show that epigenetic writers set the transcriptional permissiveness required for sustained positive regulation of blood vessel remodeling.
Smooth muscle and pericyte contractile reprogramming
In simple terms: Cells that wrap and squeeze blood vessels change their energy use and contractility, which physically reshapes the vessel.
Hexokinase 2 driven glycolysis in pericytes activates their contractility leading to tumor blood vessel abnormalities, identifying pericyte metabolic reprogramming as a positive regulator of vessel remodeling. In aortic aneurysm and dissection, histone lactylation-mediated metabolic remodeling in vascular smooth muscle cells aggravates disease by promoting lactate accumulation, showing that smooth muscle energy metabolism directly enhances remodeling. These cell-intrinsic changes increase vessel wall tone and matrix turnover, the physical hallmarks of remodeling.
Immune and inflammatory amplification
In simple terms: Immune cells release signals that amplify and sustain the remodeling response.
Macrophage CARD9 mediates cardiac injury following myocardial infarction through regulation of lipocalin 2 expression, placing an innate immune adaptor upstream of post-infarction tissue remodeling. Inflammatory amplification is a recurring feature of positive regulation of blood vessel remodeling because recruited leukocytes secrete cytokines and matrix-modifying enzymes that raise the rate of vessel-wall change.
Signaling integration and oxidative stress
In simple terms: Growth factor signals and oxidative stress are integrated to fine-tune how fast remodeling proceeds.
GATA6 coordinates cross-talk between BMP10 and the oxidative stress axis in pulmonary arterial hypertension, providing a transcriptional node that integrates growth factor and redox signals during pulmonary vascular remodeling. Clusterin is regulated in the heart and plasma of mice after transverse aortic constriction, indicating that circulating and tissue factors are coordinately adjusted during pressure-overload remodeling. These integration points determine whether remodeling remains adaptive or becomes maladaptive.
Key Genes Involved in GO:2000504 positive regulation of blood vessel remodeling
The following genes and proteins have been experimentally linked to positive regulation of blood vessel remodeling in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL14 | RNA methylation regulator whose deletion attenuates vascular ageing | Epigenetic control of age-related vascular remodeling |
| ARG1 | Drives mitochondrial cristae remodeling and PANoptosis in ischemia/hypoxia | Metabolic-inflammatory regulator of vascular dysfunction |
| LDHA | Lactate generation promoting pulmonary vascular remodeling | Glycolytic driver of pulmonary hypertension |
| HK2 | Glycolysis in pericytes activating contractility | Pericyte metabolic regulator of tumor vessel abnormalities |
| CARD9 | Macrophage adaptor mediating cardiac injury via lipocalin 2 | Innate immune amplifier of post-infarction remodeling |
| GATA6 | Coordinates BMP10 and oxidative stress cross-talk | Transcriptional integrator in pulmonary arterial hypertension |
| CLU | Clusterin regulated in heart and plasma after aortic constriction | Circulating marker of pressure-overload remodeling |
| BMP10 | Growth factor signaling input to GATA6 axis | Ligand-level control of pulmonary vascular remodeling |
| LCN2 | Lipocalin 2 downstream of CARD9 | Effector of macrophage-driven cardiac remodeling |
| Vascular smooth muscle cell metabolic machinery | Histone lactylation and lactate accumulation | Smooth muscle driver of aortic aneurysm and dissection |
| Endothelial remodeling programs | Structural reorganization of the vessel wall | General execution arm of blood vessel remodeling |
| Pericyte contractile apparatus | Contractility activated by glycolysis | Vessel stabilization and tumor vessel abnormality |
| Mitochondrial cristae machinery | Cristae remodeling under ischemia/hypoxia | Organelle-level control of vascular cell fate |
| Oxidative stress axis | Redox signaling integrated by GATA6 | Modifier of pulmonary vascular remodeling |
| Inflammatory cytokine network | Amplifies remodeling signals | Immune contribution to vessel-wall change |
| Lactate signaling | Metabolite acting as epigenetic and signaling input | Links metabolism to chromatin in remodeling |
| Matrix turnover machinery | Extracellular matrix reorganization | Structural basis of vessel remodeling |
How Is positive regulation of blood vessel remodeling Regulated?
Positive regulation of blood vessel remodeling is itself regulated at multiple levels. Upstream, hypoxia and ischemia initiate mitochondrial and inflammatory programs through ARG1. Metabolically, glycolytic enzymes such as HK2 and LDHA generate lactate that feeds both bioenergetic and epigenetic pathways, including histone lactylation in vascular smooth muscle cells. Epigenetically, METTL14-dependent methylation and lactylation marks control the accessibility of remodeling gene loci. Transcriptionally, GATA6 integrates BMP10 and oxidative stress signals in pulmonary arterial hypertension. Immune amplification through macrophage CARD9 and lipocalin 2 sustains the response after myocardial infarction, while circulating factors such as clusterin reflect systemic remodeling after pressure overload. Together these layers determine the frequency, rate and extent of blood vessel remodeling.
positive regulation of blood vessel remodeling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDHA | Pulmonary hypertension | Knockout in pulmonary vascular cells and hypoxia models |
| HK2 | Tumor blood vessel abnormalities | Pericyte-specific knockout in tumor models |
| METTL14 | Vascular ageing | Conditional knockout in aged vasculature |
| CARD9 | Myocardial infarction cardiac injury | Macrophage knockout in infarction models |
| GATA6 | Pulmonary arterial hypertension | Knockdown or knock-in in pulmonary arterial cells |
Aortic aneurysm and dissection
Histone lactylation-mediated metabolic remodeling in vascular smooth muscle cells aggravates aortic aneurysm and dissection by promoting lactate accumulation, directly linking positive regulation of blood vessel remodeling to catastrophic vessel-wall failure. This suggests that metabolic and epigenetic accelerators of remodeling are candidate therapeutic targets in aortic disease.
Pulmonary arterial hypertension
LDHA-mediated lactate generation promotes pulmonary vascular remodeling in pulmonary hypertension, and GATA6 coordinates BMP10 and oxidative stress signaling in pulmonary arterial hypertension. These findings position glycolytic and transcriptional regulators of GO:2000504 as drivers of pulmonary vascular disease.
Tumor vascular abnormalities
Hexokinase 2 driven glycolysis in pericytes activates their contractility leading to tumor blood vessel abnormalities, showing that pericyte metabolic reprogramming is a positive regulator of pathological tumor vessel remodeling. Targeting this axis may normalize tumor vasculature.
Post-infarction cardiac injury and vascular ageing
Macrophage CARD9 mediates cardiac injury following myocardial infarction through regulation of lipocalin 2 expression, and deletion of METTL14 attenuates vascular ageing. These studies connect immune and epigenetic regulators of GO:2000504 to ischemic and age-related vascular pathology.
From positive regulation of blood vessel remodeling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for vascular remodeling? | CRISPR knockout in endothelial or smooth muscle cells |
| Does a specific amino acid change alter remodeling activity? | Point-mutation knock-in at the endogenous locus |
| Does tagging reveal localization during remodeling? | Tagged knock-in of the candidate gene |
| Does excess gene activity accelerate remodeling? | Overexpression in vascular cells or transgenic models |
| Which metabolic regulators drive remodeling? | Knockout of LDHA or HK2 in disease models |
| How do epigenetic marks control remodeling genes? | METTL14 deletion and lactylation profiling |
How to Study the positive regulation of blood vessel remodeling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA sequencing | Transcriptional changes in remodeling genes | METTL14 deletion and vascular ageing |
| Lactate and glycolysis assays | Glycolytic flux and lactate accumulation | LDHA and HK2 studies |
| Electron microscopy | Mitochondrial cristae morphology | ARG1-driven vascular dysfunction |
| Histone modification profiling | Lactylation and methylation marks | Aortic aneurysm smooth muscle cells |
| Contractility assays | Pericyte and smooth muscle contraction | Tumor vessel abnormalities |
| Immunofluorescence | Protein localization in vessel wall | GATA6 and BMP10 axis |
| Plasma biomarker assays | Circulating remodeling markers | Clusterin after aortic constriction |
| Macrophage phenotyping | Immune contribution to remodeling | CARD9 and lipocalin 2 in infarction |
Transcriptomic and epigenomic profiling
RNA sequencing and chromatin-associated assays can identify genes and pathways whose expression changes when positive regulation of blood vessel remodeling is activated, as illustrated by studies of METTL14 deletion in vascular ageing and histone lactylation in aortic aneurysm. These methods define the transcriptional signature of remodeling acceleration.
Metabolic and flux measurements
Glycolytic flux, lactate production and mitochondrial cristae morphology are measurable outputs of remodeling regulators such as HK2, LDHA and ARG1. Seahorse analysis, lactate assays and electron microscopy provide quantitative readouts of metabolic control.
Imaging of vessel structure and contractility
Pericyte contractility and vessel abnormalities can be assessed by live imaging and contractility assays, as shown for hexokinase 2 driven glycolysis in pericytes. Histology and immunofluorescence of vessel walls complement these functional measurements.
Genetic perturbation and phenotyping
CRISPR knockout, point mutation and overexpression followed by disease phenotyping in aortic, pulmonary and tumor models provide causal evidence for candidate regulators of GO:2000504.
How CRISPR Can Be Used to Study GO:2000504 positive regulation of blood vessel remodeling
Knockout
CRISPR knockout of candidate genes such as METTL14, LDHA or HK2 allows direct testing of whether a regulator is required for positive regulation of blood vessel remodeling. Loss-of-function phenotypes in vascular cells and animal models establish necessity.
Point Mutation
Point-mutation knock-in can dissect specific residues required for remodeling activity, for example in metabolic enzymes or epigenetic writers whose catalytic activity drives the process. This approach separates enzymatic function from scaffolding roles.
Knock-in
Tagged knock-in of endogenous genes enables tracking of protein localization and interaction during vessel-wall remodeling, complementing fixed-tissue studies. It is particularly useful for low-abundance regulators.
Overexpression
Overexpression of candidate genes such as GATA6 or glycolytic regulators tests sufficiency, asking whether increased activity alone accelerates blood vessel remodeling. This complements knockout studies that test necessity.
How EDITGENE Supports positive regulation of blood vessel remodeling Research
Researchers studying positive regulation of blood vessel remodeling-related genes often need to determine whether a candidate gene is causally involved in accelerating vessel-wall change or is merely a downstream marker. EDITGENE provides the full spectrum of CRISPR cell models and screening services required to move from correlation to causation in vascular biology.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of blood vessel remodeling research.
Frequently Asked Questions About positive regulation of blood vessel remodeling
What is GO:2000504 positive regulation of blood vessel remodeling?
GO:2000504 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of blood vessel remodeling.
What genes are involved in positive regulation of blood vessel remodeling?
Genes experimentally linked to this process include METTL14, ARG1, LDHA, HK2, CARD9, GATA6 and CLU.
How is blood vessel remodeling regulated?
It is regulated by metabolic cues such as hypoxia and glycolysis, epigenetic marks including methylation and lactylation, and transcriptional integrators such as GATA6.
Why is positive regulation of blood vessel remodeling important in disease?
Chronic activation contributes to aortic aneurysm, pulmonary hypertension, tumor vessel abnormalities and post-infarction cardiac injury.
What role does lactate play in vascular remodeling?
Lactate generated by LDHA and glycolytic enzymes promotes pulmonary vascular remodeling and contributes to histone lactylation in aortic disease.
How does METTL14 affect vascular remodeling?
Deletion of METTL14, a key methylation regulator, attenuates vascular ageing, indicating it positively regulates age-related remodeling.
What is the role of pericytes in tumor blood vessel abnormalities?
Hexokinase 2 driven glycolysis in pericytes activates their contractility, leading to tumor blood vessel abnormalities.
How can CRISPR be used to study blood vessel remodeling?
CRISPR knockout, point mutation, knock-in and overexpression in vascular cells allow causal testing of candidate regulators.
What experimental models are used for pulmonary vascular remodeling?
Pulmonary vascular cells and animal models of pulmonary hypertension are used to study LDHA and GATA6 dependent remodeling.
What is the difference between blood vessel remodeling and positive regulation of blood vessel remodeling?
Blood vessel remodeling is the structural change itself, while positive regulation of blood vessel remodeling refers to processes that increase its frequency, rate or extent.
Conclusion
GO:2000504 positive regulation of blood vessel remodeling provides a precise ontological framework for the accelerators of vessel-wall restructuring. The cited literature shows that these accelerators span metabolic enzymes, epigenetic writers, immune adaptors and transcriptional integrators, and that their dysregulation underlies major cardiovascular and oncologic diseases. CRISPR-based causal models are essential for translating these annotations into validated therapeutic targets.
References
- 1. Liu X et al.. 2025. Deletion of METTL14, a key methylation regulator, attenuates vascular ageing.. Eur Heart J 46(45):4953-4968 PMID: 40758401
- 2. She H et al.. 2025. Arginase 1 drives mitochondrial cristae remodeling and PANoptosis in ischemia/hypoxia-induced vascular dysfunction.. Signal Transduct Target Ther 10(1):167 PMID: 40425583
- 3. Liu L et al.. 2026. Histone Lactylation-Mediated Metabolic Remodeling in Vascular Smooth Muscle Cells Aggravates Aortic Aneurysm and Dissection by Promoting Lactate Accumulation.. Circulation 153(3):189-209 PMID: 41487086
- 4. Meng YM et al.. 2021. Hexokinase 2-driven glycolysis in pericytes activates their contractility leading to tumor blood vessel abnormalities.. Nat Commun 12(1):6011 PMID: 34650057
- 5. Wu D et al.. 2024. Lactate dehydrogenase A (LDHA)-mediated lactate generation promotes pulmonary vascular remodeling in pulmonary hypertension.. J Transl Med 22(1):738 PMID: 39103838
- 6. Liu Y et al.. 2023. Macrophage CARD9 mediates cardiac injury following myocardial infarction through regulation of lipocalin 2 expression.. Signal Transduct Target Ther 8(1):394 PMID: 37828006
- 7. Turkieh A et al.. 2024. Regulation of Clusterin in the Heart and Plasma of Mice After Transverse Aortic Constriction.. J Cell Mol Med 28(23):e70290 PMID: 39671261
- 8. Toyama T et al.. 2023. GATA6 coordinates cross-talk between BMP10 and oxidative stress axis in pulmonary arterial hypertension.. Sci Rep 13(1):6593 PMID: 37087509
